Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tema Cardiovascular and Metabolic ETF (HRTS)

Tema Cardiovascular and Metabolic ETF (HRTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family Tema ETFs
  • Assets Under Management 52,300,400
  • Shares Outstanding, K 1,510
  • 60-Month Beta 0.93
  • Price/Earnings ttm 0.00
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend 0.469 on 12/11/24
  • Management Fee 0.75%

Options Overview Details

View History
  • Implied Volatility 29.21% (-1.14%)
  • Historical Volatility 18.66%
  • IV Percentile 8%
  • IV Rank 0.00%
  • IV High 95.34% on 03/17/26
  • IV Low 29.21% on 04/15/26
  • Expected Move (DTE 25) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 5
  • Put/Call OI Ratio 999.99
  • Today's Open Interest 10
  • Open Int (30-Day) 4
  • Expected Range 34.64 to 34.64

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.59 +6.27%
on 03/27/26
34.78 -0.41%
on 04/14/26
+0.71 (+2.10%)
since 03/17/26
3-Month
32.59 +6.27%
on 03/27/26
36.65 -5.49%
on 01/22/26
-1.18 (-3.29%)
since 01/16/26
52-Week
26.50 +30.70%
on 05/15/25
36.65 -5.49%
on 01/22/26
+6.95 (+25.08%)
since 04/17/25

Most Recent Stories

More News
Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing

The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp.

TCAF : 39.09 (+1.16%)
ASND : 244.48 (+0.63%)
IBB : 176.66 (+1.46%)
HRTS : 34.64 (+1.30%)
Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes

The company’s stock declined nearly 60% in 2024 and has lost an additional 21% in 2025, with this latest setback further dampening investor confidence.

VXF : 225.92 (+1.93%)
KROS : 11.67 (-0.43%)
HRTS : 34.64 (+1.30%)
XBI : 138.67 (+2.37%)
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, PPH, HRTS and THNR

For Immediate ReleaseChicago, IL – October 17, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

NVO : 40.52 (-1.00%)
LLY : 927.03 (+2.55%)
HRTS : 34.64 (+1.30%)
PPH : 104.53 (+1.67%)
THNR : 25.05 (+0.72%)
Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win

In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications, particularly GLP-1 receptor agonists such as Ozempic and Wegovy. The global...

NVO : 40.52 (-1.00%)
LLY : 927.03 (+2.55%)
HRTS : 34.64 (+1.30%)
PPH : 104.53 (+1.67%)
THNR : 25.05 (+0.72%)
Tap the Weight-Loss Drug Market With These ETFs

The weight-loss drug market is heating up with the introduction of GLP-1 pills. Novo Nordisk’s NVO Wegovy and Eli Lilly’s LLY Zepbound have been dominating this market and several other companies are...

NVO : 40.52 (-1.00%)
OZEM : 32.38 (+1.28%)
LLY : 927.03 (+2.55%)
HRTS : 34.64 (+1.30%)
RHHBY : 51.2700 (+2.68%)
THNR : 25.05 (+0.72%)
Not Sure Which Weight Loss Stock to Buy? Invest in This ETF

Many healthcare companies have been eagerly developing new weight loss drugs in an effort to cash in ...

VKTX : 35.20 (-0.87%)
LLY : 927.03 (+2.55%)
HRTS : 34.64 (+1.30%)
Don’t Know Which Weight-Loss Stock Will Be the Biggest Winner? Invest in This ETF Instead

There’s a lot of excitement in the weight-loss industry these days. Between Ozempic, Wegovy, Mounjaro, ...

NVO : 40.52 (-1.00%)
HRTS : 34.64 (+1.30%)
LLY : 927.03 (+2.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Fund Summary

The Tema Cardiovascular and Metabolic ETF seeks to provide long-term growth ofcapital by investing in companies leading the fight against diabetes, obesity and cardiovascular diseases.

See More

Top 10 Holdings

Name % Holdings

See More

Key Turning Points

3rd Resistance Point 34.98
2nd Resistance Point 34.81
1st Resistance Point 34.72
Last Price 34.64
1st Support Level 34.47
2nd Support Level 34.29
3rd Support Level 34.21

See More

52-Week High 36.65
Last Price 34.64
Fibonacci 61.8% 32.77
Fibonacci 50% 31.57
Fibonacci 38.2% 30.38
52-Week Low 26.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.